Conjunctiva – V9: 2027+
| Primary Site | Histology | Year of Diagnosis |
|---|---|---|
| C690 | 8000-8700, 8941-8960, 8965-8983, 9000, 9050-9070, 9072-9111, 9270, 9300-9312, 9340-9363, 9380-9420, 9423-9472, 9474-9493, 9501-9509, 9520-9521, 9523, 9531-9539, 9541 | 2027-9998, 9999, <BLANK> |
Notes
**See table above for primary site and histologies for this schema** C690 Conjunctiva **Note 1:** **Sources used in the development of this schema** * SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf) * SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/) * Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx * Chapter 65 *Conjunctival Carcinoma*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois. * Conjunctival Carcinoma from the AJCC Cancer Staging System Version 9 (2026). Used with permission of the American College of Surgeons, Chicago, Illinois. **Note 2:** **Other EOD Schemas with Conjunctiva sites** * **GIST**: 8935-8936 * **Kaposi Sarcoma**: 9140 * **Melanoma Conjunctiva**: 8720-8790 * **Mycosis Fungoides**: 9700-9701 * **Orbital Sarcoma**: 8710-8714, 8800-8858, 8860-8921, 8932-8934, 8940, 8963-8964, 8990, 8992, 9010-9016, 9030-9045, 9071, 9120-9138, 9141-9175, 9181-9221, 9230, 9240-9262, 9271-9290, 9320-9330, 9364-9365, 9370-9373, 9421, 9473, 9500, 9522, 9530, 9540, 9542-9582 * **Retinoblastoma**: 9510-9514 * **Soft Tissue Rare**: 8859, 8930-8931, 8991, 9020, 9180, 9222, 9231, 9366-9368Data Items
| Name | Default Value | Used in Derivation | NAACCR Item | Required By | Metadata |
|---|---|---|---|---|---|
| Year of Diagnosis | Yes |
NAACCR #390
dateOfDiagnosis |
None | ||
| Primary Site | Yes |
NAACCR #400
primarySite |
None | ||
| Histology | Yes |
NAACCR #522
histologicTypeIcdO3 |
None | ||
| Behavior | No |
NAACCR #523
behaviorCodeIcdO3 |
None | ||
| Type of Reporting Source | No |
NAACCR #500
typeOfReportingSource |
None | ||
| Tumor Size Clinical | No |
NAACCR #752
tumorSizeClinical |
None | ||
| Tumor Size Pathological | No |
NAACCR #754
tumorSizePathologic |
None | ||
| Tumor Size Summary | 999 | No |
NAACCR #756
tumorSizeSummary |
None | |
| Regional Nodes Positive | 99 | No |
NAACCR #820
regionalNodesPositive |
None | |
| Regional Nodes Examined | 99 | No |
NAACCR #830
regionalNodesExamined |
None | |
| EOD Primary Tumor | 999 | Yes |
NAACCR #772
eodPrimaryTumor |
None | |
| EOD Regional Nodes | 999 | Yes |
NAACCR #774
eodRegionalNodes |
None | |
| EOD Mets | 00 | Yes |
NAACCR #776
eodMets |
None | |
| SS2018 | No |
NAACCR #764
summaryStage2018 |
None | ||
| Grade Clinical | 9 | Yes |
NAACCR #3843
gradeClinical |
All | SSDI |
| Grade Pathological | 9 | Yes |
NAACCR #3844
gradePathological |
All | SSDI |
| Grade Post Therapy Clin (yc) | No |
NAACCR #1068
gradePostTherapyClin |
COC NPCR SEER |
SSDI | |
| Grade Post Therapy Path (yp) | No |
NAACCR #3845
gradePostTherapy |
CCCR/Canada COC NPCR SEER |
SSDI | |
| Neoadjuvant Therapy | 9 | No |
NAACCR #1632
neoadjuvantTherapy |
SEER 2021– | SSDI 2021– |
| Neoadjuvant Therapy – Clinical Response | 99 | No |
NAACCR #1633
neoadjuvTherapyClinicalResponse |
SEER 2021– | SSDI 2021– |
| Neoadjuvant Therapy – Treatment Effect | 9 | No |
NAACCR #1634
neoadjuvTherapyTreatmentEffect |
SEER 2021– | SSDI 2021– |
Initial Context
Outputs
| Name | Default Value | Description | NAACCR Item | Metadata |
|---|---|---|---|---|
| Schema ID | 09650 |
NAACCR #3800
schemaId |
None | |
| Derived Version | {{ctx_alg_version}} | None | None | |
| Derived Summary Stage 2018 | 9 |
NAACCR #762
derivedSummaryStage2018 |
None | |
| Derived Summary Grade 2018 | <BLANK> |
NAACCR #1975
derivedSummaryGrade2018 |
None |